TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05911529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: In our study intervention, patients should receive four session of motivational interviewing (MI). Throughout the MI sessions, interviewers use common MI techniques including open-ended questions, affirmations, reflections, summaries, asking permission, expressing empathy, supporting self-efficacy, etc. Interviewers are clinical psychologists who received MI training immediately prior to the study.
Study: NCT06430710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrusion
Description: 2 different methods for incisor intrusion
Study: NCT06225557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS community recommendation
Description: Enhanced recovery techniques including opioid sparing anesthesia in elective cesarean section

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional postoperative care
Description: Usual anesthesia and analgesia in elective cesarean section.
Study: NCT05231993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conization
Description: A cone biopsy to remove abnormal tissue.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colposcopy
Description: 1. Colposcopy with biopsy within 3 months,endocervical sample, ultrasound and endometrial biopsy if the woman is ≥40~2. Colposcopy after 12 months if the first colposcopy and biopsies are normal~3. Cytology and HPV testing at 12 and 24 months if the second colposcopy is normal
Study: NCT06486909

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebrospinal Fluid (CSF) Sample
Description: Samples for glucose in CSF will be taken upon EVD/LD placement until EVD/LD removal (within the first 14 days).

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Serum Sample
Description: Samples for glucose in blood serum will be completed every day, for the first 14 days.
Study: NCT05330975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT04686019

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training (IMT)
Description: IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks.
Study: NCT04569448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Adjunctive variable dose (1-3 mg/day) Brexpiprazole
Study: NCT04796636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ascorbate
Description: As previously described

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ascorbate
Description: As previously described
Study: NCT06412588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan+amoxicillin+doxycycline+bismuth for 14 days
Description: Group A:The patient was treated with oral Vonoprazan 20 mg, bid + amoxicillin 1.0 g, bid + doxycycline 0.1 g, bid + bismuth for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan+Amoxicillin
Description: Group B: Patients were treated with oral Vonoprazan 20mg, bid + amoxicillin 1.0g, bid for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan+doxycycline
Description: Group C: Patients were treated with oral Vonoprazan 20 mg, bid + doxycycline 0.1 g, bid for 14 days.
Study: NCT05330975

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Afluria® Quadrivalent
Description: single-dose, pre-filled syringe for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afluria® Quadrivalent
Description: single-dose, pre-filled syringe for injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273.214
Description: Sterile liquid for injection
Study: NCT05017623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH003
Description: All subject will receive YH003 intravenously as single agent every three weeks (Q3W) for up to 1 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first.
Study: NCT05809388

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent training
Description: Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training
Description: Parent Training program according to Ten steps of Barkley's program plus two additional follow-up sessions. This will be conducted by a trained psychologist; each session will last approximately 60 minutes and will includes exercises, discussions and role-playing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-assisted PT sessions
Description: The experimental group will follow the same program of CG sample. Parent Training sessions will be conducted by a trained psychologist; each session will last approximately 60 minutes that include:~* 40 minutes of as usual PT session, with exercises, discussions and role-playing.~* 20 minutes of VR screen with which the parents may interact; VR screen will provides instructive, stimulating, interactive, and direct feedbacks exercises to enhance parenting strategies.
Study: NCT04286178

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Description: Creatine will be taken at a dose of 150mg/kg/day of creatine base divided into 2 daily doses up to 39.7kg in body weight, after which dosing will be based on body surface area (BSA) at 4.69g/m2/day. Creatine will be administered orally as a chewable tablet provided by BioTechUSA™. Tablets are 2g and contain 0.9g of creatine monohydrate which is equivalent to 0.8g of creatine base.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ubiquinol
Description: Coenzyme Q10 (CoQ10, ubiquinol) will be taken at a dose of 10mg/kg/day divided into 2 daily doses with a daily maximum of 500mg. CoQ10 will be administered orally in 50mg softgels containing 50mg of ubiquinol (Active Q®), provided by Tishcon Corporation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose tablet
Description: Creatine placebo will be in the form of a glucose tablet with identical appearance and taste to the active supplement. The number of tablets/day will be determined based on the dose of creatine required for each patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: gel capsule
Description: Ubiquinol placebo will be in the form of a gel capsule with identical appearance to the active supplement. The number of capsules/day will be determined based on the dose of ubiquinol required for each patient.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be coached to hit 12,000 steps or 60 active minutes per day as logged by a FitBit (FitBit calculates active minutes as activities equivalent to moderate-to-vigorous physical activity (MVPA) done continuously for at least 10 minutes)
Study: NCT05780879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax administered orally once daily on days 3-16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAG or CLAG Protocol
Description: FLAG consists of daily infusions of Fludarabine (30mg/m2/day over 30 minutes) and Ara-C (2g/m2/day over 4 hours) for 5 days with daily subcutaneous injections of G-CSF until count recovery. Tbo-filgrastim will be administered as follows: WBC count \>50,000 - 5mcg/kg; WBC count \<50,000 - hold Tbo-filgrastim. Given the national shortage of Fludarabine, Cladrabine (5mg/m2/day IV over 2 hours) has been substituted (CLAG) with similar toxicity profile.
Study: NCT05794607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Description: The intervention group will be given strength training to improve muscle strength and flexibility, and aerobic exercise training to improve exercise capacity with function.
Study: NCT05911529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive conversations
Description: In the control intervention patients should also be given four sessions, in which no MI techniques take place. They will be carried out in the sense of supportive conversations (i. e. conver-sations that do not follow a specific psychotherapy concept).~Since we want to check whether the patients really benefit from the specific intervention and not from getting more speaking time, the patient in the control group will also be given four conver-sations. It is known that supportive conversations can have a certain effect on the well-being and recovery process of patients, as the therapeutic relationship, i.e. appreciation, attention and/or attention, is an important efficacy factor (e. g. Grawe, 1995).
Study: NCT05664490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youth Friendship Bench SA
Description: The intervention includes: 5 individual counseling sessions; one optional in-person or WhatsApp-based group counseling session; optional remote counseling sessions; and optional one-way SMS messages to provide reminders about upcoming visits. During the initial session, participants will meet with the trained counselor to discuss mental health challenges, identify problems in their life that affect their mental health and PrEP use, generate alternative solutions, make decisions about the alternatives, and collaboratively decide on a plan to implement the solutions. During follow-up counseling sessions, participants will discuss progress in implementing solutions to address the problems they identified in prior sessions with the lay counselor. They will also discuss any other mental health challenges and problems in their life that affect their mental health and PrEP use which they would like to address.
Study: NCT06255353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube Feeding according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including intracranial pressure reduction, anti-infection therapy, blood pressure and blood glucose control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study: NCT06546462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: The active arm will receive osteopathic manipulative treatment which is a hands-on treatment modality use to treat a variety of health concerns.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Light touch arm
Description: Sham arm will receive a light touch sham treatment.
Study: NCT05007964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatz4 Adjustable Balloon System
Description: The Spatz4 Adjustable Balloon System is designed to assist weight loss by partially filling the stomach and inducing satiety. The intragastrical balloon is implanted endoscopically for up to 12 months.
Study: NCT06201676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Injection
Description: Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin Reference ID: 3281582 3 synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium Chloride Injection, USP is sterile and nonpyrogenic. It is a parenteral solution containing sodium chloride in water for injection intended for intravenous administration. Each 100 mL of 0.9% Sodium Chloride Injection, USP contains 900 mg sodium chloride in water for injection. Electrolytes per 1000 mL: sodium (Na+) 154 mEq; chloride (Cl-) 154 mEq. The osmolarity is 308 mOsmol/L (calc.).
Study: NCT06061692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tongxinluo Capsule
Description: 4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxinluo Capsule
Description: 4 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
Study: NCT04686019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: IMT and conventional neurorehabilitation - treatment as usual. The intervention group will add-on IMT sessions exercising at 30 % of MIP. MIP is measured by instructing the patient to perform five forceful inspirations against an occluded mouthpiece (Power Breath). The best score is multiplied by 0.3 to determine the resistance. IMT is performed with IMT Threshold flute with the calculated resistance. During the measurement with Power Breath the patient sits straight up and uses nose clip. The patient can receive help to hold the Power Breath if necessary.~One session of IMT with IMT threshold flute consists of 2 times 15 inspirations in normal breathing rhythm (5-10 min). Patients in the intervention group perform 2 sessions a day (morning and evening), training is performed prior to a meal, 7 days a week for 3 weeks.
Study: NCT06322524

Intervention type: DEVICE
Intervention: Gamma sensory flicker
Description: participants were exposed to flicker stimulation through a light and sound device, the flicker was 40 Hz.
Study: NCT06111924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented circuit training based telerehabilitation
Description: Task oriented circuit training based telerehabilitation (TOCT-TR) via video conference call will be provided for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinic based Task oriented circuit training
Description: Clinic based Task oriented circuit training (TOCT-CR) will be provided in clinic as in person training for 6 weeks, thrice a week in total18 sessions. Total 15 exercises will be performed by patient in a session of 60 minutes. Duration per exercise will be 3 minutes and a rest interval of 1 will be provided after each exercise.
Study: NCT06299228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Sensorimotor intervention, active range of motion, active assisted range of motion, strengthening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Active range of motion, active assisted range of motion and strengthening
Study: NCT04771351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT04644341

Intervention type: COMBINATION_PRODUCT
Intervention: cardiovascular and respiratory systems monitoring
Description: only one group of individuals to observe the impact of COVID-19 on their cardiovascular and respiratory systems in long term.
Study: NCT05493449

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: UHT Milk
Description: In this group of participants, UHT milk, 180 mL was provided and results were compared with control and flavored milk group

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Flavored Milk
Description: In this group of participants, flavored milk, 180 mL was provided and results were compared with control and UHT group
Study: NCT06137105

Intervention type: DRUG
Intervention: eltrombopag and romiplastim
Description: Group I: eltrombopag and romiplastim~Group II : recived corticosteroid.

Intervention type: DRUG
Intervention: eltrombopag and romiplastim
Description: Group I: eltrombopag and romiplastim~Group II : recived corticosteroid.
Study: NCT05325931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kalifilcon A Daily Disposable Multifocal
Description: kalifilcon A Daily Disposable Multifocal low add and high

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: samfilcon A for Presbyopia
Description: Ultra for Presbyopia Low and High Add Contact Lenses
Study: NCT04955431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction
Description: Participants will be allowed \~4 hour sleep opportunity during the restricted night of sleep prior to reporting to lab for a simulated firefighting session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Sleep
Description: Participants will be allowed \~8 hour sleep opportunity the night of sleep prior to reporting to lab for a simulated firefighting session.
Study: NCT05510206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leveling and alignment
Description: Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leveling and alignment
Description: Polishing, Bonding of appliance, placement of the first arch wire for Super elastic NiTi group then the second wire after two months taking study model each month during the study For Smartarch Group placing experimental arch wire for 4 months , taking impression each month.~For both groups peri-apical X-Ray to lower anterior teeth is taken prior to treatment and 4 months later, also visual pain analogue scale is taken for 7 days after placing archwires
Study: NCT05496322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Non Invasive Blood Pressure Monitoring
Description: Continuous non-invasive arterial pressure monitoring